mCRPC Market: Growth Momentum Across 7MM to 2034 - DelveInsight

DelveInsight's "Metastatic Castrate-resistant Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Metastatic Castrate-resistant Prostate Cancer, historical and forecasted epidemiology as well as the Metastatic Castrate-resistant Prostate Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Metastatic Castrate-resistant Prostate Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Metastatic Castrate-resistant Prostate Cancer Market Forecast
https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Metastatic Castrate-resistant Prostate Cancer Market Report:
• The Metastatic Castrate-resistant Prostate Cancer market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In September 2025, Jyong Biotech Ltd. (Nasdaq: MENS), a Taiwan-based, science-driven biotechnology company dedicated to developing and commercializing innovative plant-derived drugs, primarily targeting urinary system diseases with initial focus on the U.S., EU, and Asian markets, announced the completion of patient enrollment in its Phase II clinical trial of MCS 8, an investigational therapy for prostate cancer prevention (PCP). Since the trial's initiation, over 700 high-risk subjects have been enrolled, marking a significant milestone in the company's clinical development program.
• In December 2025, The FDA has issued full approval for rucaparib (Rubraca) to treat adult patients with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) who have previously received androgen receptor-targeted therapy. This approval is based on results from the phase 3 TRITON3 trial (NCT02975934), where rucaparib (n = 201) demonstrated a significant improvement in radiographic progression-free survival compared with physician's choice of treatment (n = 101) among patients with BRCA mutations, achieving a median rPFS of 11.2 months (95% CI, 9.2-13.8) versus 6.4 months (95% CI, 5.4-8.3), respectively (HR, 0.50; 95% CI, 0.36-0.69; P < .0001).
• In February 2025, Alda Therapeutics, a clinical-stage biotech company advancing a new class of cancer treatments known as RIPTACTM (Regulated Induced Proximity Targeting Chimeras) therapeutics, has announced that the first patient has been dosed in its Phase 1/2 first-in-human clinical trial (NCT06800313). The study will assess the safety and tolerability of HLD-0915 for patients with metastatic castration-resistant prostate cancer (mCRPC).
• In 2023, there were about 7,279,500 prevalent cases of prostate cancer across the 7MM, and this figure is anticipated to grow between 2024 and 2034 due to an aging population and improvements in diagnostic methods.
• The United States recorded around 1,093,300 five-year prevalent cases of prostate cancer in 2023.
• Within the EU4 and the UK, Germany reported the highest number of metastatic CRPC cases in 2023, whereas Spain reported the lowest.
• Analysis indicates that in the US, roughly 40% of prostate cancer cases are identified in people aged 65-74 years, making this the most affected age group.
• Estimates suggest that in the US, localized or locally advanced prostate cancer (Stage I-III) accounted for about 56% of all cases in 2023, while nearly 33% were biochemical recurrence/progressive cases, and approximately 11% were metastatic cases.
• In 2023, the US had around 51,100 metastatic CRPC cases, with numbers expected to rise throughout the forecast period.
• Key Metastatic Castrate-resistant Prostate Cancer Companies: Janssen Research & Development, Pfizer, AstellasPharma, Bristol-Myers Squibb, Promontory Therapeutics, Hinova, Arcus Biosciences, Inc., AB Science, Suzhou Kintor Pharma, Tracon Pharma, Bayer, AstraZeneca, Clarity Pharma, Novartis, Endocyte, EMD Serono, Medivation, Inc., POINT Biopharma, and others
• Key Metastatic Castrate-resistant Prostate Cancer Therapies: Niraparib, Talzenna, Opdivo (nivolumab), Talazoparib, PT-112, HC-1119, Etrumadenant, Masitinib, GT0918, TRC253, Radium-223 dichloride, AZD4635, 64Cu-SAR-bisPSMA, 68Ga-PSMA-11, 177Lu-PSMA-617, EMD 525797, Darolutamide, Enzalutamide, [Lu-177]-PNT2002, and others
• The Metastatic Castrate-resistant Prostate Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Metastatic Castrate-resistant Prostate Cancer pipeline products will significantly revolutionize the Metastatic Castrate-resistant Prostate Cancer market dynamics.

Metastatic Castrate-resistant Prostate Cancer Overview
CRPC that has spread to other organs has a bad prognosis and a shorter survival time. In comparison to men with localised prostate cancer, who have a 100% 5-year survival rate, men with metastatic prostate cancer have an estimated 5-year survival rate of roughly 30%.

Get a Free sample for the Metastatic Castrate-resistant Prostate Cancer Market Report
https://www.delveinsight.com/report-store/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Metastatic Castrate-resistant Prostate Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Metastatic Castrate-resistant Prostate Cancer Epidemiology Segmentation:
The Metastatic Castrate-resistant Prostate Cancer market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Metastatic Castrate-resistant Prostate Cancer
• Prevalent Cases of Metastatic Castrate-resistant Prostate Cancer by severity
• Gender-specific Prevalence of Metastatic Castrate-resistant Prostate Cancer
• Diagnosed Cases of Episodic and Chronic Metastatic Castrate-resistant Prostate Cancer

Download the report to understand which factors are driving Metastatic Castrate-resistant Prostate Cancer epidemiology trends @ Metastatic Castrate-resistant Prostate Cancer Epidemiology Forecast
https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Metastatic Castrate-resistant Prostate Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic Castrate-resistant Prostate Cancer market or expected to get launched during the study period. The analysis covers Metastatic Castrate-resistant Prostate Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Metastatic Castrate-resistant Prostate Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Metastatic Castrate-resistant Prostate Cancer Therapies and Key Companies
• Niraparib: Janssen Research & Development
• Talzenna: Pfizer/AstellasPharma
• Opdivo (nivolumab): Bristol-Myers Squibb
• Talazoparib: Pfizer
• PT-112: Promontory Therapeutics
• HC-1119: Hinova
• Etrumadenant: Arcus Biosciences, Inc.
• Masitinib: AB Science
• GT0918: Suzhou Kintor Pharma
• TRC253: Tracon Pharma
• Radium-223 dichloride: Bayer
• AZD4635: AstraZeneca
• 64Cu-SAR-bisPSMA: Clarity Pharma
• 68Ga-PSMA-11: Novartis
• 177Lu-PSMA-617: Endocyte
• EMD 525797: EMD Serono
• Darolutamide: Bayer
• Enzalutamide: Medivation, Inc.
• [Lu-177]-PNT2002: POINT Biopharma

Discover more about therapies set to grab major Metastatic Castrate-resistant Prostate Cancer market share @ Metastatic Castrate-resistant Prostate Cancer Treatment Market
https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Metastatic Castrate-resistant Prostate Cancer Market Strengths
• The development of therapies targeting specific mutations are expected to perform better in the upcoming future (e.g.PARP inhibitors).
• Companies are now attempting to enter the first-line setting, particularly Taxane-naive settings, to reduce the need for chemotherapy in patients with mCRPC

Metastatic Castrate-resistant Prostate Cancer Market Opportunities
• Uptake of potential emerging therapies with better clinical profile, specially targeting the mutations like PARP inhibitors (i.e., BRCA mutation) expected to be fast.
• Rising prevalence of prostate cancer due to rapidly aging population and growing awareness among people will provide the larger window of opportunity for new treatment

Scope of the Metastatic Castrate-resistant Prostate Cancer Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Metastatic Castrate-resistant Prostate Cancer Companies: Janssen Research & Development, Pfizer, AstellasPharma, Bristol-Myers Squibb, Promontory Therapeutics, Hinova, Arcus Biosciences, Inc., AB Science, Suzhou Kintor Pharma, Tracon Pharma, Bayer, AstraZeneca, Clarity Pharma, Novartis, Endocyte, EMD Serono, Medivation, Inc., POINT Biopharma, and others
• Key Metastatic Castrate-resistant Prostate Cancer Therapies: Niraparib, Talzenna, Opdivo (nivolumab), Talazoparib, PT-112, HC-1119, Etrumadenant, Masitinib, GT0918, TRC253, Radium-223 dichloride, AZD4635, 64Cu-SAR-bisPSMA, 68Ga-PSMA-11, 177Lu-PSMA-617, EMD 525797, Darolutamide, Enzalutamide, [Lu-177]-PNT2002, and others
• Metastatic Castrate-resistant Prostate Cancer Therapeutic Assessment: Metastatic Castrate-resistant Prostate Cancer current marketed and Metastatic Castrate-resistant Prostate Cancer emerging therapies
• Metastatic Castrate-resistant Prostate Cancer Market Dynamics: Metastatic Castrate-resistant Prostate Cancer market drivers and Metastatic Castrate-resistant Prostate Cancer market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Metastatic Castrate-resistant Prostate Cancer Unmet Needs, KOL's views, Analyst's views, Metastatic Castrate-resistant Prostate Cancer Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.